Ask a facility design engineer what’s changed most about biologics manufacturing in the past five years, and the answer usually isn’t a specific technology. It’s a design brief: build something that doesn’t need to be right forever.
Why Flexibility Became the Design Brief
A biologics facility commissioned today will almost certainly manufacture a different product mix in five years than the one it was designed around. Pipelines shift. A commercial-scale monoclonal antibody program gets joined — or replaced — by a smaller-volume bispecific, an ADC, or a cell and gene therapy campaign with batch sizes an order of magnitude smaller. CDMOs, by design, don’t know their full future client roster at groundbreaking.
Fixed stainless-steel infrastructure doesn’t absorb that kind of change well. A 2,000L train sized and validated around one process doesn’t easily become the right platform for a 200L personalized-medicine campaign two years later. That mismatch — between what a facility was engineered for and what it eventually needs to run — is the actual problem flexible design is solving. It isn’t a buzzword. It’s a hedge against the fact that nobody can fully predict a product pipeline five years out.
The Ballroom Concept — And What Actually Makes It Work
The clearest expression of this shift is the move toward “ballroom” facility layouts: open-plan manufacturing floors where multiple unit operations share a single classified space instead of being separated into individually walled, airlocked suites.
Ballroom design isn’t new as an architectural idea. What makes it viable for biologics specifically is closed processing. In a traditional segregated layout, physical walls and airlocks do the job of preventing cross-contamination between operations. In a ballroom, that job shifts to the fluid pathway itself — bioprocess bags, sterile connectors, and closed transfer lines that never expose product to the surrounding room air. If the process is genuinely closed, the room classification protecting it can often be lower than the process itself would otherwise demand, and multiple operations can share floor space without contaminating each other.
This is precisely where single-use storage plays its most underappreciated role. XELTA 2D bags handling buffer hold and intermediate storage, and XELTA 3D bags handling larger-volume process fluids, aren’t just tank replacements — they’re what makes an open floor plan defensible from a contamination-control standpoint. A fixed stainless tank in a ballroom is a contamination risk waiting for an incident report. A closed, single-use bag on a mobile cart is a contained fluid pathway that can be relocated, reconfigured, or removed entirely between campaigns.
Modular cleanroom construction extends the same logic to the building itself. Prefabricated cleanroom pods, built and qualified off-site and craned into position, compress construction timelines from years to months and let a facility add capacity in discrete increments rather than committing to a single build-out on day one. Paired with single-use process equipment, this gives facility planners a genuinely staged expansion path — build the footprint you need now, and know exactly what adding the next increment costs, in both capital and schedule.
Upstream Flexibility Starts With Mixing
Buffer and media preparation is one of the least glamorous parts of a biologics facility and one of the most consistently underestimated in early layout planning. A fixed stainless mixing tank commits a facility to a specific volume range and demands its own CIP skid, utility drops, and cleaning validation cycle — overhead that scales poorly when you’re preparing a dozen different buffer formulations across multiple concurrent campaigns.
Levitation-based single-use mixing — the approach behind PharmNXT’s NXTmix platform — sidesteps most of that. A magnetically levitated impeller inside a single-use bag eliminates the mechanical seals and bearings that create both contamination risk and cleaning burden in traditional mixers, and the same hardware skid can run a meaningfully different volume range simply by swapping the single-use bag rather than requalifying a tank. For a facility planning around unpredictable future formulation needs, that flexibility at the mixing stage matters more than it might seem — buffer and media prep sits upstream of nearly everything else, and rigidity here creates scheduling bottlenecks downstream.
Downstream Modularity: Filtration, TFF, and Chromatography as Building Blocks
Downstream processing is where fixed infrastructure historically created the most inflexibility, simply because purification trains are usually engineered tightly around a specific molecule and process. Single-use technology’s contribution here isn’t just disposability — it’s the ability to reconfigure a purification skid’s function without reconfiguring its footprint.
Tangential flow filtration is a good illustration. PharmNXT’s NXTtff platform runs fully automated UF/DF operations across a 20L to 500L range using interchangeable cassette configurations from 0.5 to 2.5 m² — meaning the same automation skid can support a small-batch clinical campaign and a larger commercial run without a different piece of capital equipment for each. Low hold-up volume matters disproportionately here: for a high-value biologic, every millilitre left behind in tubing or a filter housing after a run is lost product, and hold-up volume as a proportion of batch size only gets worse at smaller scales — exactly the scales personalized medicine and cell and gene therapy are pushing facilities toward.
The same modularity logic applies to sterile and virus filtration — where a platform like NXTmfilt is built to accommodate different filter types and configurations across clarification, bioburden reduction, and virus removal rather than requiring separate dedicated skids for each — and to chromatography, where configurable platforms like NXTchrom let a single hardware footprint support multiple resin types and column configurations as a product’s purification strategy evolves from process development through commercial scale.
The Fluid Pathway Is the Real Design Problem
Here’s what doesn’t show up on an equipment list but consumes a disproportionate share of engineering time in practice: every one of these unit operations needs to be connected to the others, and no two processes need exactly the same connection.
This is the part of facility design that single-use manifold and assembly systems exist to solve. PharmNXT’s XELTA KoNXT assemblies are essentially a customization layer for the fluid pathway — configurable combinations of tubing, connectors, and clamps built for a specific function (in-process sampling, product transfer, buffer transfer, filling) but assembled from a defined, validated component set rather than engineered from scratch each time. The engineering value isn’t the individual assembly. It’s that a facility running multiple products can standardize how sampling ports, transfer lines, and filling assemblies get built, even when the products themselves are completely different.
That distinction — standardized components, customized configuration — is what actually makes multi-product flexibility manufacturable rather than just theoretically possible.
Defined Tubing Routing: An Engineering Philosophy, Not Just a Product
If there’s one design decision that separates facilities that run smoothly from facilities that generate a disproportionate share of their deviations from something as mundane as tubing, it’s routing discipline.
In most single-use manufacturing suites, tubing routing has historically been left to operator judgment at the point of assembly — run the line where it fits, clamp it where it’s convenient. That approach seems harmless until you look at what it actually produces: no two setups of the “same” process look identical, trip hazards accumulate on the floor, tubing crosses over itself in ways that create pinch points and flow restrictions, and troubleshooting a flow anomaly means first figuring out how this particular operator routed this particular run.
Defined Tubing Routing treats this as a design problem rather than an operator-judgment problem. The routing path for a given assembly is engineered once, documented with the same rigor as a P&ID, and then installed identically every time — typically using a physical routing structure that fixes tubing paths at defined heights and positions rather than leaving them to run along the floor or drape across equipment. PharmNXT’s DTR platform, developed through its acquisition of an Ireland-based tubing engineering specialist, approaches routing this way: as a repeatable, documented configuration rather than a per-run assembly decision, supporting bioprocess volumes from 20L to 500L with defined spans up to 2.9 metres.
The engineering payoff compounds across several dimensions at once. Installation becomes faster because operators are following a fixed path rather than making layout decisions. Operator error drops because there’s one correct configuration instead of open-ended judgment calls. Validation becomes more defensible because the routing is part of the qualified assembly, not a variable outside it. Troubleshooting gets faster because a deviation investigation isn’t complicated by not knowing how this particular run was physically configured. And maintenance planning improves because a facility can standardize spare tubing lengths and connector inventories around a known set of routing configurations instead of stocking for infinite variability.
None of this is dramatic on its own. Collectively, it’s the difference between a facility that treats single-use assembly as a repeatable manufacturing process and one that treats it as a craft exercise performed slightly differently by every operator on every shift.
The Design Details That Separate Good Facilities From Great Ones
A handful of engineering considerations tend to determine whether a flexible facility actually performs, beyond the equipment selection itself.
Dead-leg elimination deserves attention at the manifold design stage, not as a post-commissioning fix — every unused branch in a fluid pathway is a zone where flow stagnates and bioburden can accumulate, and it’s far cheaper to design it out of a KoNXT assembly than to discover it during a contamination investigation.
Ergonomic layout is not a soft consideration. Tubing and connection points positioned outside comfortable operator reach get installed incorrectly more often, and routing structures that keep lines at working height rather than floor level measurably reduce both installation error and physical trip hazards on the manufacturing floor.
Utility optimization follows naturally from single-use adoption but is worth designing around explicitly — a facility that has eliminated most CIP/SIP cycles can rightsize its WFI, clean steam, and cleaning-agent infrastructure accordingly, rather than carrying utility capacity sized for a stainless-steel facility it no longer resembles.
Containment deserves separate treatment for potent compound handling — ADCs, HPAPI intermediates, and similar applications — where powder transfer between processing steps needs to maintain containment integrity. Split butterfly valve systems, like PharmNXT’s NXTvalve SBV, exist specifically to move powder between two containment boundaries without operator exposure or cross-contamination, and they belong in the same design conversation as fluid-pathway single-use technology even though the engineering problem they solve is different.
Scalability and maintenance planning, taken together, are really a question about what happens to a facility’s operating model once single-use is central to it: maintenance shifts from mechanical uptime (agitator seals, CIP skid reliability) toward supply chain reliability (consumable lead times, assembly consistency), and scalability becomes less about re-engineering fixed equipment and more about qualifying a new assembly configuration on hardware that’s already validated.
Why Annex 1 Effectively Endorses This Design Direction
The 2022 revision of EU GMP Annex 1 didn’t invent the ballroom concept, but it made closed processing the regulatory expectation rather than an optional design choice. The Contamination Control Strategy that Annex 1 now requires is, in practice, easiest to build around a facility where the fluid pathway is closed and documented — because a documented, standardized single-use configuration gives you a much cleaner risk narrative than an open-process facility trying to justify its controls after the fact.
This has a direct design implication: validation and documentation infrastructure needs to be planned alongside the physical layout, not bolted on afterward. Standardized assemblies — the same KoNXT configuration, the same DTR routing, used consistently across campaigns — generate validation evidence that compounds in value over time, because each qualified use adds to a body of process knowledge about that specific configuration rather than starting from zero with each new setup.
Where This Is Playing Out Across Asia
Flexibility as a design priority is showing up earliest and most visibly where facility investment is happening fastest. South Korea’s large CDMOs are building next-generation campuses explicitly designed around multi-modality production — antibody-drug conjugates, cell and gene therapy, and biologics on shared or adjacent infrastructure — which is a ballroom problem by definition. Singapore’s biomanufacturing precincts, anchored around Tuas Biomedical Park, increasingly favor facility designs that can pivot between modalities as multinational tenants’ pipelines evolve.
Across Malaysia, Thailand, Indonesia, and Vietnam, the calculus is different but points the same direction: these are markets building first- and second-generation biologics capacity without the certainty of a stable, single-product manufacturing mandate. A facility that commits its capital to one fixed process is a much riskier bet in a market still establishing its product pipeline than one designed to absorb whatever comes next. India’s expanding CDMO and biosimilar sector faces a similar reality, running multiple client programs through shared infrastructure where standardized, flexible single-use platforms are what make that multi-tenancy operationally workable rather than a scheduling nightmare.
In every one of these markets, flexibility isn’t an aspiration bolted onto the facility brief. It’s increasingly the brief itself.
The Facility of the Next Decade
The next generation of biologics facilities across Asia is likely to be more digital, more modular, and more standardized simultaneously — and those three things reinforce each other more than facility planners sometimes appreciate. Digital process monitoring works best on standardized equipment configurations, because sensor placement and data architecture can be designed once and replicated. Modular construction works best when the process equipment inside each module is itself flexible enough not to dictate the module’s permanent function. And standardization — of assemblies, of routing, of manifold configurations — is what makes both of the others practical to validate and maintain at scale.
That last point is worth sitting with. For most of the last decade, competitive advantage in bioprocess equipment was framed around innovation — a better bag, a faster filter, a smarter sensor. Standardization is becoming just as important a design lever, because a facility that can install, validate, and troubleshoot its single-use systems consistently will outperform one running more sophisticated equipment less predictably.
Companies building toward that standard — manufacturing in India, supplying into 14-plus countries, and increasingly designed into facilities being built by leading biopharma manufacturers across the region — are, in effect, the ones defining what a genuinely engineered single-use ecosystem looks like, as distinct from a catalogue of disposable parts. That distinction is likely to matter more over the next decade than any single product innovation.
Closing Thought
Flexibility in biomanufacturing facility design was never really about single-use technology as an end in itself. It’s about designing a physical asset that can absorb a decade of pipeline uncertainty without becoming obsolete or over-built.
The facilities getting this right aren’t the ones with the most advanced individual components. They’re the ones where every design decision — the floor plan, the mixing platform, the fluid pathway, the tubing routing, the documentation architecture — was made with the next unknown product in mind, not just the one currently on the process sheet.
That’s not a product specification. It’s a design philosophy. And it’s quietly becoming the most important one in the industry.
#BioprocessEngineering #FacilityDesign #SingleUseSystems #Biomanufacturing #ModularFacilities #CDMOAsia #Annex1 #ProcessEngineering #BiopharmaAsia #PharmNXTBiotech
